fda compounding semaglutide enforcement news today 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA to Restrict Ingredients Used

Short-acting GLP-1RA (e.g., exenatide, lixisenatide) more prominently delays gastric emptying [70] but generally produces more modest and earlier-plateauing weight loss [71]

Lets explores the potential of Dihexa in treating Parkinsons disease, highlighting its mechanism of action and the supporting scientific research

It protects skin from sun rays

Who Benefits Most From Low-Dose GLP-1 Therapy Patients with obesity-related genetic predispositionssuch as variants in the FTO gene or MC4R genemay see meaningful weight loss even at microdoses because their metabolic challenges are being directly addressed

This is the first step toward developing that knowledge, which will require large-scale, carefully controlled clinical trials. Huda Akil, Ph.D., the co-director and research professor at the Molecular and Behavioral Neuroscience Institute (MBNI) at the University of Michigan, tells GEN that severe, untreatable depression is remarkably difficult to unpack biologically with multiple paths to becoming depressed (genetic, development, metabolic, social). Because of this complexity, one treatment will not work for everyone. In addition to finding that patients with MDD have less LAC in their blood, the researchers were able to identify subtypes of patient populations based on their LAC levels